Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients

Damci T. , YALIN S., Balci H. , Osar Z., KORUGAN Ü., ÖZYAZAR M. , ...More

DIABETES CARE, vol.27, pp.1077-1080, 2004 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 5
  • Publication Date: 2004
  • Doi Number: 10.2337/diacare.27.5.1077
  • Title of Journal : DIABETES CARE
  • Page Numbers: pp.1077-1080


OBJECTIVE - Orlistat leads to improved glycemic control in obese type 2 diabetic patients, which is attributed to decreased insulin resistance associated with weight loss. Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are gut hormones that are secreted in response to food intake, and they both stimulate insulin secretion. Orlistat decreases fat absorption and increases intestinal fat content, which may lead to increased secretion of these peptides. In this pilot study, we tested the hypothesis that increased levels of these intestinal hormones may be involved in the improvement of postprandial hyperglycemia observed previously with orlistat in type 2 diabetic patients.